Sorafenib (LuciSora) 200mg*120's | Lucius Laos Generic | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

分享
Product description

Generic Information: LuciSora (Laos)

LuciSora is a Laotian generic of sorafenib produced by Lucius Pharmaceuticals. Each tablet contains 200 mg of sorafenib tosylate, supplied in a 120-tablet pack that covers a full month of treatment. Lucius Pharmaceuticals has built a reputation for quality oncology generics, and LuciSora is its sorafenib offering for patients seeking an affordable alternative to the originator.

What Is LuciSora Used For?

LuciSora is prescribed for unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and radioactive-iodine-refractory differentiated thyroid carcinoma. It is a first-line oral targeted therapy for advanced liver cancer and a standard option for advanced kidney cancer, with the 120-tablet pack convenient for continuous monthly dosing.

How Does Sorafenib Work?

The active ingredient blocks CRAF/BRAF and the receptors VEGFR-2/3, PDGFR-beta, c-Kit and FLT3. This dual inhibition of cancer-cell growth and tumour blood-vessel formation slows progression across the three approved indications.

Indications

Approved uses are unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and differentiated thyroid carcinoma refractory to radioactive iodine. Treatment requires an oncology specialist's diagnosis and prescription.

Dosage

The standard dose is 400 mg twice daily (800 mg total per day) on an empty stomach. The 120-tablet pack provides 30 days of treatment at this dose. The dose is reduced stepwise when side effects become difficult to tolerate.

Side Effects

Common side effects are hand-foot skin reaction, diarrhoea, fatigue, rash, hypertension, nausea and hair thinning. Serious but uncommon effects include liver toxicity, bleeding, cardiac events and gastrointestinal perforation. Regular monitoring is essential during treatment.

Storage

Store at room temperature in a dry place, away from light, in the original pack, and keep out of reach of children. Do not use beyond the expiry date.

Why Choose the GLT?

LuciSora delivers a full month of sorafenib in one pack at a price far below the originator's Western list price. Sourcing through GLT ensures genuine Lucius product with significant savings compared with United States or European pharmacy costs, helping patients sustain long-term therapy.

How to Order

Message GLT on WhatsApp at +86 15234153837 or email [email protected] to order LuciSora. We confirm availability, price and international shipping from our Hong Kong-licensed facility before you order.

FAQ

Who manufactures LuciSora? LuciSora is made by Lucius Pharmaceuticals, a Laotian company known for quality oncology generics.

Is LuciSora the same as Nexavar? Yes, it is a generic containing the same sorafenib active ingredient, for the same indications.

How many tablets are in a pack? LuciSora comes in a 120-tablet pack, which is a full month of treatment at the standard dose.

Related Oncology Products

Tixepa(替尔泊肽)20mg/2mL 和 30mg/2mL 多剂量注射笔 | Drug International | GLT

Tixepa——Drug International Limited (DIL) 替尔泊肽多剂量注射笔,两种官方规格(Tixepa-5=20mg/2mL,Tixepa-7.5=30mg/2mL)用于 2 型糖尿病和肥胖。

KeZeRui 科瑞泽(阿伐曲泊帕)20mg*10片 | 四川科伦(中国)| GLT

KeZeRui——四川科伦药业的国采阿伐曲泊帕,中国一体化原料药+片剂制造商。

Baricent(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Incepta Pharmaceuticals Ltd. | GLT

由 Incepta Pharmaceuticals Ltd.(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Barinat(巴瑞替尼)4mg | 仿制 JAK1/JAK2 抑制剂 | Natco Pharma Limited | GLT

由 Natco Pharma Limited(印度)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Palutini(巴瑞替尼)4mg | 仿制 JAK1/JAK2 抑制剂 | Trans Continental Life Science & Pharmaceuticals (TLPH) | GLT

由 Trans Continental Life Science & Pharmaceuticals (TLPH)(老挝)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Avabopa(阿伐曲泊帕)20mg*30片 | 老挝东盟制药 TLPH | GLT

Avabopa——老挝东盟制药(TLPH)阿伐曲泊帕 20mg,老挝注册号 07 L 0990/23

奥氟格列隆/奥格列龙(OriYo)0.8–17.2mg 片剂 | 孟加拉仿制药 口服 GLP-1 | GLT

孟加拉国民制药(National Drug Co.)仿制奥氟格列隆,6 剂量递增用于体重管理